Myocarditis With COVID-19 mRNA Vaccines
- PMID: 34281357
- PMCID: PMC8340726
- DOI: 10.1161/CIRCULATIONAHA.121.056135
Myocarditis With COVID-19 mRNA Vaccines
Abstract
Myocarditis has been recognized as a rare complication of coronavirus disease 2019 (COVID-19) mRNA vaccinations, especially in young adult and adolescent males. According to the US Centers for Disease Control and Prevention, myocarditis/pericarditis rates are ≈12.6 cases per million doses of second-dose mRNA vaccine among individuals 12 to 39 years of age. In reported cases, patients with myocarditis invariably presented with chest pain, usually 2 to 3 days after a second dose of mRNA vaccination, and had elevated cardiac troponin levels. ECG was abnormal with ST elevations in most, and cardiac MRI was suggestive of myocarditis in all tested patients. There was no evidence of acute COVID-19 or other viral infections. In 1 case, a cardiomyopathy gene panel was negative, but autoantibody levels against certain self-antigens and frequency of natural killer cells were increased. Although the mechanisms for development of myocarditis are not clear, molecular mimicry between the spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and self-antigens, trigger of preexisting dysregulated immune pathways in certain individuals, immune response to mRNA, and activation of immunologic pathways, and dysregulated cytokine expression have been proposed. The reasons for male predominance in myocarditis cases are unknown, but possible explanations relate to sex hormone differences in immune response and myocarditis, and also underdiagnosis of cardiac disease in women. Almost all patients had resolution of symptoms and signs and improvement in diagnostic markers and imaging with or without treatment. Despite rare cases of myocarditis, the benefit-risk assessment for COVID-19 vaccination shows a favorable balance for all age and sex groups; therefore, COVID-19 vaccination is recommended for everyone ≥12 years of age.
Keywords: COVID-19; COVID-19 vaccines; SARS-CoV-2; mRNA vaccine; myocarditis; pericarditis; vaccination.
Figures
![Figure 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8340726/bin/cir-144-471-g003.gif)
![Figure 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8340726/bin/cir-144-471-g006.gif)
![Figure 3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8340726/bin/cir-144-471-g007.gif)
Similar articles
-
Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.PLoS Med. 2023 Jun 7;20(6):e1004245. doi: 10.1371/journal.pmed.1004245. eCollection 2023 Jun. PLoS Med. 2023. PMID: 37285378 Free PMC article.
-
COVID-19 vaccine-associated myocarditis.World J Cardiol. 2022 Jul 26;14(7):382-391. doi: 10.4330/wjc.v14.i7.382. World J Cardiol. 2022. PMID: 36161056 Free PMC article. Review.
-
Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.PLoS Med. 2022 Jul 28;19(7):e1004056. doi: 10.1371/journal.pmed.1004056. eCollection 2022 Jul. PLoS Med. 2022. PMID: 35900992 Free PMC article.
-
Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series.Rev Med Virol. 2022 Jul;32(4):e2318. doi: 10.1002/rmv.2318. Epub 2021 Dec 17. Rev Med Virol. 2022. PMID: 34921468 Review.
-
Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older.JAMA Intern Med. 2021 Dec 1;181(12):1668-1670. doi: 10.1001/jamainternmed.2021.5511. JAMA Intern Med. 2021. PMID: 34605853 Free PMC article.
Cited by
-
RNA m5C methylation modification: a potential therapeutic target for SARS-CoV-2-associated myocarditis.Front Immunol. 2024 Apr 23;15:1380697. doi: 10.3389/fimmu.2024.1380697. eCollection 2024. Front Immunol. 2024. PMID: 38715608 Free PMC article. Review.
-
The Epidemiology of COVID-19 Vaccine-Induced Myocarditis.Adv Med. 2024 Apr 18;2024:4470326. doi: 10.1155/2024/4470326. eCollection 2024. Adv Med. 2024. PMID: 38681683 Free PMC article. Review.
-
A novel deep generative model for mRNA vaccine development: Designing 5' UTRs with N1-methyl-pseudouridine modification.Acta Pharm Sin B. 2024 Apr;14(4):1814-1826. doi: 10.1016/j.apsb.2023.11.003. Epub 2023 Nov 5. Acta Pharm Sin B. 2024. PMID: 38572113 Free PMC article.
-
COVID-19 Vaccine-Induced Myocarditis and Pericarditis: Towards Identification of Risk Factors.Glob Heart. 2023 Jul 31;18(1):39. doi: 10.5334/gh.1252. eCollection 2023. Glob Heart. 2023. PMID: 38533475 Free PMC article. No abstract available.
-
Pediatric Chest Pain: A Review of Diagnostic Tools in the Pediatric Emergency Department.Diagnostics (Basel). 2024 Mar 1;14(5):526. doi: 10.3390/diagnostics14050526. Diagnostics (Basel). 2024. PMID: 38473000 Free PMC article. Review.
References
-
- Su JR, McNeil MM, Welsh KJ, Marquez PL, Ng C, Yan M, Cano MV. Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990–2018. Vaccine. 2021;39:839–845. doi: 10.1016/j.vaccine.2020.12.046 - PubMed
-
- Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP). Coronavirus disease 2019 (COVID-19) vaccines. Accessed July 6, 2021. https://www.cdc.gov/vaccines/acip/meetings/slides-2021-06.html
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous